Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Moodys
AstraZeneca
Express Scripts
McKinsey
Johnson and Johnson

Last Updated: December 7, 2022

Details for Patent: 8,513,299


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,513,299 protect, and when does it expire?

Patent 8,513,299 protects SILENOR and is included in one NDA.

This patent has eleven patent family members in four countries.

Summary for Patent: 8,513,299
Title:Methods of using low-dose doxepin for the improvement of sleep
Abstract: Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).
Inventor(s): Rogowski; Roberta L. (Rancho Santa Fe, CA), Dube; Susan E. (Carlsbad, CA), Jochelson; Philip (San Diego, CA)
Assignee: Pernix Sleep, Inc. (The Woodlands, TX) Procom One, Inc. (San Marcos, TX)
Application Number:11/804,720
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,513,299
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,513,299

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Currax SILENOR doxepin hydrochloride TABLET;ORAL 022036-001 Mar 17, 2010 AB RX Yes No See Plans and Pricing See Plans and Pricing TREATMENT OF INSOMNIA See Plans and Pricing
Currax SILENOR doxepin hydrochloride TABLET;ORAL 022036-002 Mar 17, 2010 AB RX Yes Yes See Plans and Pricing See Plans and Pricing TREATMENT OF INSOMNIA See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,513,299

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2687118 See Plans and Pricing
Canada 2687124 See Plans and Pricing
European Patent Office 2026792 See Plans and Pricing
Japan 2009537553 See Plans and Pricing
Japan 2009537554 See Plans and Pricing
Japan 2013237694 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Harvard Business School
McKesson
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.